OIPE JC85 MAY 03 2004 PATENT & TRADEMARK OFFICE

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 9

Complete if Known	
Application Number	10/672,585
Filing Date	September 26, 2003
First Named Inventor	Gosselin, *et al.*
Group Art Unit	To be assigned
Examiner	To be assigned
Attorney Docket Number	18085.105102 EMU 120 CIP 3

3455881 1.DOC

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. [1]	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pgs, Clmns, Lns, Where Relevant Passages/Relevant Figs Appear
AO	AA	3,116,282	A	Hunter, et al.	12-31-1963	
	AB	3,553,192	A	Gauri, et al.	01-05-1971	
	AC	4,000,137	A	Dvonoch, et al.	12-28-1976	
	AD	4,140,761	A	Gerin, et al.	02-20-1979	
	AE	4,336,381	A	Nagata, et al.	06-22-1982	
	AF	4,818,538	A	Rideout, et al.	04-04-1989	
	AG	4,861,759	A	Mitsuya, et al.	08-29-1989	
	AH	4,879,277	A	Mitsuya, et al.	11-07-1989	
	AI	4,900,828	A	Belica, et al.	02-13-1990	
	AJ	4,916,122	A	Chu, et al.	04-10-1990	
	AK	4,963,533	A	de Clercq, et al.	10-16-1990	
	AL	5,041,449	A	Belleau, et al.	08-20-1991	
	AM	5,047,407	A	Belleau, et al.	09-10-1991	
	AN	5,059,690	A	Zahler, et al.	10-22-1991	
	AO	5,089,500	A	Daluge	02-18-1992	
	AP	5,149,794	A	Yatvin, et al.	09-22-1992	
	AQ	5,151,426	A	Belleau, *et al.*	09-29-1992	
	AR	5,179,104	A	Chu, *et al.*	01-12-1993	
	AS	5,185,437	A	Koszalka, *et al.*	02-09-1993	
	AT	5,194,654	A	Hostetler, *et al.*	03-16-1993	
	AU	5,204,466	A	Liotta, *et al.*	04-20-1993	
	AV	5,210,085	A	Liotta, *et al.*	05-11-1993	
	AW	5,223,263	A	Hostetler, *et al.*	06-29-1993	
	AX	5,234,913	A	Furman, Jr.	08-10-1993	
	AY	5,248,776	A	Chu, *et al.*	09-28-1993	
	AZ	5,256,641	A	Yatvin, *et al.*	10-26-1993	
	AAA	5,270,315	A	Belleau, *et al.*	12-14-1993	
	AAB	5,276,151	A	Liotta	01-04-1994	
	AAC	5,411,947	A	Hostetler, *et al.*	05-02-1995	
AO	AAD	5,444,063	A	Schinazi	08-22-1995	

Examiner Signature	Howard Cao	Date Considered	12-6-04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submitted for form 1449/PTO

IPE
MAY 0 3 2004
PATENT & TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 2 of 9

Complete if Known	
Application Number	10/672,585
Filing Date	September 26, 2003
First Named Inventor	Gosselin, *et al.*
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	18085.105102 EMU 120 CIP 3

3455881 1.DOC

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. [1]	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pgs, Clmns, Lns, Where Relevant Passages/Relevant Figs Appear
HO	BA	5,463,092	A	Hostetler, *et al.*	10-31-1995	
	BB	5,466,806	A	Belleau, *et al.*	11-14-1995	
	BC	5,486,520	A	Belleau, *et al.*	01-23-1996	
	BD	5,532,246	A	Belleau, *et al.*	07-02-1996	
	BE	5,539,116	A	Liotta, *et al.*	07-23-1996	
	BF	5,543,389	A	Yatvin, *et al.*	08-06-1996	
	BG	5,543,390	A	Yatvin, *et al.*	08-06-1996	
	BH	5,543,391	A	Yatvin, *et al.*	08-06-1996	
	BI	5,554,728	A	Basava, *et al.*	09-10-1996	
	BJ	5,587,362	A	Chu, *et al.*	12-24-1996	
	BK	5,587,480	A	Belleau, *et al.*	12-24-1996	
	BL	5,770,713	A	Imbach	06-23-1998	
	BM	5,770,725	A	Gosselin, et al.	06-23-1998	
HO	BN	5,849,905	A	Gosselin, et al.	12-15-1998	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. [1]	Foreign Patent Document Office [3]	Number	Kind Code [2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document DD-MM-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T [6]
HO	BO	EP	0 217 580	A2	Wellcome Foundation Ltd.	04-08-1987		
	BP	EP	0 285 884	A2	Bristol-Myers Company	10-12-1988		
	BQ	EP	0 337 713	B1	Biochem Pharma	10-18-1989		
	BR	EP	0 350 287	A2	Vical Inc.	01-10-1990		
	BS	EP	0 352 248	A1	Medivir Aktiebolag	01-24-1990		
	BT	EP	0 375 329	A2	Wellcome Foundation Ltd.	06-27-1990		
	BU	EP	0 382 526	A2	IAF Biochem International	08-16-1990		
	BV	EP	0 433 898	A2	Abbott Laboratories	06-26-1991		
	BW	EP	0 494 119	A1	IAF Biochem International	07-08-1992		
	BX	EP	0 515 144	A1	Biochem Pharma	11-25-1992		
	BY	EP	0 515 156	A1	Biochem Pharma	11-25-1992		
	BZ	EP	0 515 157	A1	Biochem Pharma	11-25-1992		
HO	BAA	EP	0 526 253	A1	Biochem Pharma	02-03-1993		

Examiner Signature	Harold Pless	Date Considered	12-6-04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

* Not in file

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submitted for form 1449/PTO

PATENT & TRADEMARK OFFICE
MAY 03 2004

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 3 of 9

Complete if Known	
Application Number	10/672,585
Filing Date	September 26, 2003
First Named Inventor	Gosselin, *et al.*
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	18085.105102 EMU 120 CIP 3

3455881 1.DOC

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. [1]	Foreign Patent Document: Office [3]	Number	Kind Code [2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document DD-MM-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T [6]
AO	CA	WO	88/07532	A1	Nycomed	10-06-1988		
	CB	WO	88/08001	A1	Aktiebolaget Astra	10-20-1988		
	CC	WO	89/02733	A1	University of California	04-06-1989		
	CD	WO	90/00555	A1	Vical Inc.	01-25-1990		
	CE	WO	90/12023	A1	Walker; Jones	10-18-1990		
	CF	WO	91/11186	A1	Emory University	08-08-1991		
	CG	WO	91/16920	A1	Vical Inc.	11-14-1991		
	CH	WO	91/17159	A1	IAF Biochem International Inc.	11-14-1991		
	CI	WO	91/18914	A1	Vical Inc.	12-12-1991		
	CJ	WO	91/19721	A1	Glazier	12-26-1991		
	CK	WO	92/00315	A1	CNRS	01-09-1992		
	CL	WO	92/06102	A1	Medivir Aktiebolag	04-16-1992		
	CM	WO	92/08717	A1	IAF Biochem International Inc.	05-29-1992		
	CN	WO	92/08727	A1	Consiglio Nazionale delle Ricerche	05-29-1992		
	CO	WO	92/10496	A1	Univ. Georgia Res. Found.	06-25-1992		
	CP	WO	92/10497	A1	Univ. Georgia R.F.; Emory Univ.	06-25-1992		
	CQ	WO	92/14729	A1	Emory University	09-03-1992		
	CR	WO	92/14743	A2	Emory University	09-03-1992		
	CS	WO	92/15308	A1	Wellcome Foundation Ltd.	09-17-1992		
	CT	WO	92/18517	A1	Yale Univ.; Univ. Georgia R.F.	10-29-1992		
	CU	WO	92/21676	A1	Glaxo Group Ltd.	12-10-1992		
	CV	WO	93/00910	A1	Vical Inc.	01-21-1993		
	CW	WO	93/12128	A1	C.N.R.S.	06-24-1993		
	CX	WO	93/12131	A1	C.N.R.S.	06-24-1993		
	CY	WO	93/12132	A1	C.N.R.S.	06-24-1993		
	CZ	WO	93/24510	A1	C.N.R.S.	12-09-1993		
	CT	WO	94/04154	A1	Univ. Georgia R.F.; Emory Univ.	03-03-1994		
	CU	WO	94/05300	A1	Biochem Pharma Inc.	03-17-1994		
WHO	CV	WO	94/09793	A1	Emory University	05-11-1994		

Examiner Signature		Date Considered	12-6-04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

* 16 in file

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submitted for form 1449/PTO				*Complete if Known*	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	**10/672,585**
				Filing Date	**September 26, 2003**
				First Named Inventor	**Gosselin, *et al.***
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	4	of	9	Attorney Docket Number	**18085.105102 EMU 120 CIP 3**

3455881 1.DOC

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. [1]	Foreign Patent Document: Office [3]	Number	Kind Code [2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document DD-MM-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T [6]
*	DA	WO	94/14456	A1	Biochem Pharma Inc.	07-07-1994		
	DB	WO	94/14802	A1	Biochem Pharma Inc.	07-07-1994		
	DC	WO	94/26273	A1	Hostetler	11-24-1994		
	DD	WO	94/26764	A1	C.N.R.S.	11-24-1994		
	DE	WO	94/27616	A1	Yale University	12-08-1994		
	DF	WO	95/07086	A1	Emory; CNRS; UAB Res. Found.	03-16-1995		
	DG	WO	95/07287	A1	C.N.R.S.	03-16-1995		
	DH	WO	95/11252	A1	C.N.R.S.	04-27-1995		
	DI	WO	95/20595	A1	Univ. Georgia R. F.; Yale Univ.	08-03-1995		
	DJ	WO	96/15132	A1	University of California	05-23-1996		
	DK	WO	96/40164	A1	Emory; UAB Res. Found.; CNRS	12-19-1996		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. [1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [6]
*	DL	ASSELINE, *et al.*, "Synthesis and Physicochemical Properties of Oligonucleotides built with either alpha-L or beta-L Nucleotides Units and Covalently Linked to an Acridine Derivative," *Nucleic Acids Res.*, 19 (15):4067-4074 (1991).	
	DM	AYOOLA, *et al.*, "Progress in the Control of Viral Hepatitis: Memorandum from a WHO Meeting," *Bulletin of the World Health Organization*, 66(4):443-455 (1988).	
	DN	BALZARINI, J., "Potent and selective anti-HTLV-III/LAV activity of 2',3'-dideoxycytidinene, the 2',3'-unsaturated derivative of 2',3'-dideoxycytidine," *et al.*, *Biochem. Biophys. Res. Comm.*, 140(2): 735-742 (October 30, 1986).	
	DO	BEACH, J.W., *et al.*, "Synthesis of EnantiomericallyPure (2'R,5'S)-(-)-1-[2 (hydroxymethyl)-oathiolan-5-yl]Cytosine...," *J. Org. Chem.*, 57:2217-2219 (1992).	
	DP	BEASLEY, *et al.*, "Hepatocellular Carcinoma and Hepatitis B Virus," *The Lancet*, 1129-1133 (1981).	
	DQ	BELLEAU, B., *et al.*, "Design and Activity of a Novel Class of Nucleoside Analogs...," *Intl. Conf. on AIDS*, Montreal, Quebec, Canada, June 4-9, 1989.	
	DR	BOUTELJE, *et al.*, *Chemical Abstracts*, 108:128048 (1987).	
	DS	CARTER *et al.*, "Activities of (-)-carbovir and 3'-azido-3'-deoxythymidine against human immunodeficiency virus in vitro," *Antimicrob. Agents Chemother.*, 34(6):1297-1300 (June 1990).	

Examiner Signature		Date Considered	12-6-04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

* Not in file

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submitted for form 1449/PTO				*Complete if Known*	
				Application Number	10/672,585
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	September 26, 2003
				First Named Inventor	Gosselin, *et al.*
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	5	of	9	Attorney Docket Number	18085.105102 EMU 120 CIP 3

3455881 1.DOC

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. [1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [6]
*	EA	CHANG, C., *et al.*, "Production of Hepatitis B Virus in *vitro* by Transient Expression ...," *EMBO J.*, 6(3):675-680 (1987).	
	EB	CHANG, C.-N., *et al.*, "Deoxycytidine Deaminase-resistant Steroisomer is the Active Form of (+)-2'-3'-Thiacytidine in the Inhibition of Hepatitis B Virus Replication," *J. Biol. Chem.*, 267(20):13938-13942 (1992).	
	EC	CHANG, C-N., *et al.*, "Biochemical Pharmacology of (+) and (-)-2',3'-Dideoxy-3'Thioacytidine as Anti-Hepatitis B Virus Agents," *J. Biol. Chem.*, 267(31):22414-22420 (1992).	
	ED	CHU, C.K., *et al.*, "An Efficient Total Synthesis of 3'-Azido-3'-Deoxythiymidine (AZT) and 3'-Azido-2',3'-Dideoxyuridine (AZDDU, CS-87) from D-Mannitol," *Tetrahedron Lett.*, 29(42):5349-5352 (1988).	
	EE	CHU, *et al.*, "Structure Activity Relationships of Pyrimide Nucleosides as Antiviral Agents for Human Immunodeficiency Virus Type 1 in Peripheral Blood Mononuclear Cells." *J, Med. Chem.*, 32:612 (1989).	
	EF	CHU, *et al.*, "Asymmetric Synthesis of Enantiomerically Pure (-)-(l'R,4'R)-Dioxolane-thymine and Its Anti-HIV Activity," *Tetrahedron Letters*, 32(31):3791-3794 (1991).	
	EG	CHU, *et al.*, "Comparative Activity of 2',3'-Saturated and Unsaturated Pyrimidine and Purine Nucleosides ...," *Biochem. Pharm.* 37(19):3543-3548 (1988).	
	EH	CHU, *et al.*, "Enantiomeric Synthesis of (+)-BCH-189[(+)-(2S,5R)-l-(Hydroxymethyl) 1,3-oxathiolane-5-yl]cytosine] from D-Mannose and Its Anti-HIV Activity," *J. Org. Chem.*, 56:6503-6505 (1991).	
	EI	CHU, *et al.*, "Synthesis and Anti-HIV and Anti-HBV Activity of Enantiomerically Pure Oxathiolane Nucleosides," *Antiviral Research*, 17(S1):2 (March 1992).	
	EJ	CHU, *et al.*, "Synthesis and Biological Evaluation of D-(2S) and L-(2R)-I,3 Oxathiolanyl-and D-(2R)- and L-(2S)-l,3-Dioxolanyl-Nucleosides as Anti-HIV and Anti-HBV Agents," *Antiviral Research*, 30(S1):192 (April 1993).	
	EK	COATES, J., *et al.*, "The Separated Enantiomers of 2'-deoxy-3'-thiacytidine (BCH-189) Both Inhibit Human Immunodeficiency Virus Replication In Vitro," *Antimicrob. Agents Chemother.* 36(1):202-205 (1992).	
	EL	CRETTON, E., *et al.*, "Catabolism of 3'-Azido-3'-Deoxythymidine in Heptaocytes and Liver Microsomes, with Evidence of Formation of 3'-Amino-3'-Deoxythymidine a Highly Toxic Catabolite for Human Bone Marrow Cells," *Molecular Pharmacology*, 39:258-266 (1991).	
	EM	CRETTON, E., *et al.*, "Pharmokinetics of 3'-Azido-3'-Dexoythymidine and its Catabolites and interactions with Probenecid in Rhesus Monkeys," Antimicrobial Agents and Chemotherapy, 35(5):801-807 (1991).	
	EN	DI BISCEGLIE, A.M., *et al.*, "Hepatocellular Carcinoma," NIH Conference, *Annals of Internal Medicine*, 108:390-401 (1988).	

Examiner Signature		Date Considered	12-6-04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

* Not in file

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submitted for form 1449/PTO				*Complete if Known*	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	**10/672,585**
				Filing Date	**September 26, 2003**
				First Named Inventor	**Gosselin, *et al.***
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	6	of	9	Attorney Docket Number	**18085.105102 EMU 120 CIP 3**

3455881 1.DOC

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. [1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [6]
*	FA	DOONG, S.-L., *et al.*, "Inhibition of the Replication of Hepatitis B virus *in vitro* by 2',3'-Dideoxy-3'-Thiacytidine and Related Analogues," *Natl. Acad. Sci. USA*, 88:8495-8499 (1991).	
	FB	FURMAN, *et al.*, "The Anti-Hepatitis B Virus Activities, Cytotoxicities, and Anabolic Profiles of the (-) and (+) Enantiomers of *cis*-5-Fluoro-1-[2-(Hydromethyl)-1,3-Oxathiolane-5-yl) Cytosine," *Antimicrob. Agents and Chemo.*, 36(12):2686-2692 (1992).	
	FC	GANEM, "Animal Models of Hepatitis B Virus," *Experimental Models in Antimicrobial Chemotherapy*, 2:259-272 (1986).	
	FD	GANEM, D., *et al.*, "The Molecular Biology of the Hepatitis B Viruses," *Ann. Rev. Biochem.*, 56:651-693 (1987).	
	FE	GOSSELIN, et al, " Improved and New Synthetic Procedures, Methods, and Techniques," *Nucleic Acid Chemistry*, PJ4, L. B. Townsend and R. S. Tipan, eds, John Wiley & Sons, Inc. (1991), p. 41.	
	FF	GOSSELIN, G., "Enantiomeric 2',3'-Deoxycytidine Derivatives are Potent Human Immunodeficiency Virus Inhibitors in Cell Cultures," *Compt.Rend.. Acad. Sci. Paris Sci. Vie.* 317:85-89 (1994).	
	FG	HAMAMOTO, Y., *et al.*, "Inhibitory effect of 2',3'-didehydro-2',3'-dideoxynucleosides on infectivity, cytopathic effects, and replication of human immunodeficiency virus," *Antimicrob. Agents. Chemother.*, 31(6):907 (June 1987).	
	FH	HOONG, *et al.*, "Enzyme-Mediated Enantioselective Preparation of Pure Enantiomers of the Antiviral Agent 2'3'-Dideoxy-5-Fluoro-3'-Thiacytidine (FTC) and Related Compounds," *J. Org. Chem.*, 57:5563-5565 (1992).	
	FI	JEONG, *et al.*, "An Efficient Synthesis of Enantiomerically Pure (+)-(2S,5R)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-y;]cytosine [(+)-BCH-189] from D-Galactose," *Tetrahedron Letters*, 33(5):595-598 (1992).	
	FJ	JEONG, L., *et al.*, "Asymmetric Synthesis and Biological Evaluation of β-L-(2R,5S)-and a-L-(2R-5R)-1,3-Oxathiolane-0Pyrimidine and -Purine Nucleosides ad Potential Anti-HIV Agents," *J. Med. Chem.*, 36(2):181-195 (1993).	
	FK	JONES & BISCHOFBERGER, "Minireview: nucleotide prodrugs," *Antiviral Research*, 27:1-17 (1995).	
	FL	JUROVCIK & HOLY, "Metabolism of pyrimidine L-nucleosides," *Nucleic Acid Research*, 3(8):2143-2154 (1976).	
	FM	KASSIANIDES, C., *et al.*, "Inhibition of Duck Hepatitis B Virus Replication by 2',3'-Dideoxycytidine," *Gastroenterology*, 97(5):1275-1280 (1989).	
	FN	KIM, *et al.*, "L-β-(2S,4S)-and L-α-(2S,4R)-Dioxolanyl Nucleosides as Potential Anti-HIV Agents: Asymmetric Synthesis and Structure-Activity Relationships," *J. Med. Chem.*, 36(5):519-528 (1993).	
	FO	KIM, H.O., *et al.*, "1,3-Dioxolanylpurine Nucelosides (2R,4R) and (2R,4S) with Selective Anti-HIV-1 Activity in Human Lymphocytes," *J. Med. Chem.*, 36(1):30-37 (1993).	

Examiner Signature	Harold Pless	Date Considered	12-6-04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

* Not in file

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submitted for form 1449/PTO				*Complete if Known*	
				Application Number	10/672,585
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	September 26, 2003
				First Named Inventor	Gosselin, *et al.*
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	7	of	9	Attorney Docket Number	18085.105102 EMU 120 CIP 3

3455881 1.DOC

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. [1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [6]
HO	GA	KIM, H.O., *et al.*, "Potent Anti-HIV and Anti-HBV Activities of (-)-L-β-Dioxolane-C and (+)-L-β-Dioxolane-T and Their Asymmetric Syntheses," *Tetrahedron Lett.*, 33(46):6899-6902 (1992).	
	GB	KRENITSKY, T.A., *et al.*, "3'-Amino-2'3'-Dideoxyribonucleosides of Some Pyrimidines: Synthesis and Biological Activities," *J. Med. Chem.*, 26(6) 891-895 (1983.)	
	GC	KUKHANOVA, M., *et al.*, "L-and D-Enantiomers of 2',3'-Dideoxycytidine 5'-Triphosphate Analogs as Substrates for Human DNA Polymerases," *J. Biol. Chem.*, 270(39):23056-23059 (1995).	
	GD	LEE, B., *et al.*, "*In Vitro* and *In Vivo* Comparison of the Abilities of Purine and Pyrimidine 2',3'-Dideoxynucleosides To Inhibit Duck Hepadnavirus," *Antimicrob. Agents and Chemother.*, 33(3):336-339 (1989).	
	GE	LIN, *et al.*, "Potent and Selective In Vitro Activity of 3'-Deoxythmindine-2-Ene-(3'-Deoxy-2',3'-Didehydrothymidine) Against Human Immunodeficiency Virus," *Biochem. Pharm.* 36(17):2716 (1987).	
	GF	MAHMOUDIAN, M., *et al.*, "Enzymatic Production of Optically Pure (2'R-cis)-2;-deoxy-3'tiacytidine (3TC,Lamivudine): A Potent Anti-HIV Agent," published by the Glaxo Group Research ltd., *Enzyme Microb. Technol.*, 15:749-755 (1993).	
	GG	MANSURI, M.M., *et al.*, "Preparation of the Geometric Isomers of DDC, DDA, D4C, and D4T. . ."," *Bioorg. Med. Chem. Lett.*, 1:65-68 (1991).	
	GH	MATTHES, E., *et al.*, "Potent Inhibition of Hepatitis B Virus Production in Vitro by Modified. . .," *Antimicrob. Agents and Chemo.*, 34(10):1986-1990 (1990).	
	GI	MILLER, R.H., *et al.*, "Common Evolutionary Origin of Hepatitis B Virus and Retroviruses," *Proc. Natl. Acad. Sci. USA*, 83:2531-2535 (1986).	
	GJ	MITSUYA, H., *et al.*, "3'-Azido-3'-Deoxythymidine (BW A 509U): An antiviral Agent that Inhibits and Infectivity and Cytopathic Effect of Human T-Lymphotropic Virus type III/Lymphadenopathy-Associated Virus in Vitro," *Proc. Natl. Acad. Sci. USA*, 82:7097-7100 (1985).	
	GK	MITSUYA, H., *et al.*, "Molecular Targets for AIDS Therapy, "*Science*, 249:1533-1544 (1990).	
	GL	MITSUYA, H., *et al.*, "Rapid in Vitro Systems for Assessing ...," AIDS: Modern Concepts and Therapeutic Challenges, S. Broder, Ed. pp. 303, Marcel-Dekker, New York (1987).	
	GM	NORBECK, D., *el al.*, "A New 2'3'-Dideoxynucleoside Prototype with In Vitro Activity Against HIV," *Tetrahedron Lett*, pp. 6263-6266 (1989).	
	GN	NORIN, *Chemical Abstracts*, 108:146380 (1987).	
	GO	OHNO, *et al.*,*Chemical Abstracts*, 112:194612 (1989).	
	GP	OKABE, M., *et al.*, "Synthesis of the Dideoxynucleosides ddC and CNT from Glutamic Acid, Ribonolactone, and Pyrimidine Bases," *J. Org. Chem.* 53(20): 4780-4786, (1988).	
HO	GQ	PAI, S.B., *et al.*, "Inhibition of Hepatitis B Virus by a Novel L-Nucleoside, 2'-Fluoro-5-Methyl-β-L-Arabinofuranosyl Uracil," *Antimicrobial Agents and Chemotherapy*, 40(2):380-386 (1996).	

Examiner Signature	Howard Cass	Date Considered	12-6-04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

* Not in file

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submitted for form 1449/PTO				*Complete if Known*	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/672,585
				Filing Date	September 26, 2003
				First Named Inventor	Gosselin, *et al.*
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	8	of	9	Attorney Docket Number	18085.105102 EMU 120 CIP 3

3455881 1.DOC

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. [1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [6]
*	HA	PERIGAUD, C., *et al.*, "Equal Inhibition of the Replication of Human Immunodeficiency Virus in Human T-cell Culture by ddA Bis(SATE)phosphotriester and 3'-Azido-2',3'-dideoxythymidine," *Biochem. Pharmacol.* 48(1):11-14 (July 5, 1994).	
	HB	PIANTADOSI, C., *et al.*, "Synthesis and evaluation of novel ether lipid nucleoside conjugates for anti-HIV-1 activity," *J. Med. Chem.*, 34(4):1408-1414 (April 1991).	
	HC	RICHMAN, D.D., *et al.*, "The Toxicity of Azidothymidine (AZT) in the Treatment of patients with AIDS and AIDS-related complex. A Double-blind, Placebo-controlled Trial," *N. Eng. J. Med.*, 317(4):192-197 (23 July 1987).	
	HD	RYAN, K.J. *et al.*, "9-β-L-Riboufuranosyladenine ("L-Adenosine"), Synthetic Procedures in Nucleic Acid Chemistry, Vol, 1, pp. 163-167, Interscience Publishers, New York, NY (1968).	
	HE	SATSUMABAYASHI, S. *et al.*, "The Synthesis of 1,3-Oxathiolane-5-one Derivatives, "*Bull, Chem. Soc. Japan*, 45:913-915 (1972).	
	HF	SCHINAZI, *et al.*, "Pure Nucleoside Enantiomers of β-2',3'-Dideoxycytidine Analogs are Selective Inhibitors of Hepatitis B Virus in Vitro," *Antimicrob. Agents and Chemother.*, 38(9):2172-2174 (1994).	
	HG	SCHINAZI, R.F., *et al.*, "Comparison of inhibitory activities of various antiretroviral agents against particle-derived and recombinant human immunodeficiency virus type 1 reverse transcriptases," *Antimicrob. Agents Chemother*, 33(1):115-117 (January 1989).	
	HH	SCHINAZI, R.F. *et al.*, "Activities of the Four Optical Isomers of 2',3"-Dideoxy-3'-Thiacytidine ...," *Antimicrob. Agents & Chemo.*, 36(3):672-676 (1992).	
	HI	SCHINAZI, R.F., *et al.*, "Insights into HIV Chemotherapy, "*AIDS Research and Human Retroviruses* 8(6):963-989 (1992).	
	HJ	SCHINAZI, R.F., *et al.*, "Pharmacokinetics and Metabolism of Racemic 2',2'-Dideoxy-5...," *Antimicrob. Agents and Chemother.*, 36(11)2432-2438 (1992).	
	HK	SCHINAZI, R.F., *et al.*, "Rapid Communications: Substrate Specificity of Escherichia Coli, Thymidine Phosphorylase for Pyrimidine Nucleoside with an Anti-Human Immunodeficiency Virus Activity, " *Bioch. Pharm.*, 44(2):199-204 (1992).	
	HL	SCHINAZI, R.F., *et al.*, "Selective Inhibition of Human Immunodeficiency Viruses by Racemates and Enantiomers of cis-5-Fluoro-1-[2-(Hydroxymethyl)-1,3-Oxathiolan-5-yl) Cytosine, "*Antim. Agents and Chemo.*, 36(11):2423-2431 (1992).	
	HM	SELLS, M.A., *et al.*, Production of Hepatitis B Virus Particles in Hep G2 Cells," *Proc. Natl, Acad. Sci. USA*, 84:1005-1009 (1997).	
*	HN	SOUDEYNS, H., *et al.*, "Anti-Human Immunoodeficiency Virus Type 1 Activity and Vitro Toxicity of 2'-Deoxy-3'-Thiacytidine...," *Antimicrob. Agents and Chemother.*, 35(7):1386-1390 (1991).	

Examiner Signature	Howard Flynn	Date Considered	12-6-04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

* Not in file

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submitted for form 1449/PTO				*Complete if Known*	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	**10/672,585**
				Filing Date	**September 26, 2003**
				First Named Inventor	**Gosselin, *et al.***
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	9	of	9	Attorney Docket Number	**18085.105102 EMU 120 CIP 3**

3455881 1.DOC

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
HD	IA	SPADARI, *et al.*, "L-Thymidine Is Phosphorylated by Herpes Simplex Virus Type 1 Thymidine Kinase and Inhibits Viral Growth" *J. Med. Chem.*, 35: no. 22, 4214-4220, (1992).	
	IB	ST. CLAIR, M.H., *et al.*, "3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase," *Antimicrob. Agents Chemother.*, 31(12):1972-1977 (December 1987).	
	IC	STERZYCKI, R.Z. *et al.*, "Synthesis and Anti-HIV Activity of Several 2'-Fluoro-Containing Pyrimidine Nucleosides," *J. Med. Chem.*, 33(8):2150-2157 (1990).	
	ID	STORER, R., *et al.*, "The Resolution and Absolute Stereochemisty of the Enantiomers of cis-1-[2-(Hydromethyl)-1,3-Oxathiolan-5-yl)cytosine (BCH-189): Equipotent Anti-HIV Agents," *Nucleosides & Nucleotides*, 12(2):225-236 (1993).	
	IE	SU, T.-A., *et al.*, "Nucleosides. 136. Synthesis and Antiviral Effects and Several 1-(2-Deoxy-2-Fluoro-β-D-Arabinofuranousyl)-5Alkyluracils. Some Structure- Activity Relationships, *J. Med. Chem.*, 29(1):151-154 (1986).	
	IF	SUREAU, C., *et al.*, "Production of Hepatitis B Virus by a Differentiated Human Hepatoma Cell Line after Transfection with Cloned Circular HBV DNA," *Cell*, 47:37-47 (1986).	
	IG	TSURIMOTO, T., *et al.*, "Stable Expression and Replication of Hepatitis B Virus Genome ...," *Proc. Natl, Acad. Sci. USA*, 84:444-4448 (1987).	
	IH	VOLK, W.A., editor, "Hepatitis," Essentials of Medical Microbiology, J.B. Lippincott Company, (Philadelphia/Toronto) 2nd Ed., pp. 609-618 (1982).	
	II	VORBRÜGGEN, *et al.*, "Nucleoside Synthesis with Trimethylsily Triflate and Perchlorate as Catalyst," *Chem. Ber.*, 114:1234-1255 (1981).	
	IJ	WATANABE, K.A., *et al.*, "Synthesis and anti-HIV-1 activity of 2'-"up"-fluoro analogues of active anti-AIDS nucleosides 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxycytidine (DDC)," *J. Med. Chem.*, 33(8):2145-2150 (August 1990).	
	IK	WILSON, L.J., *et al.*, "A General Method for Controlling Glycosylation Sterochemistry in the Synthesis ...," *Tetrahedron Lett.*, 31(13):1815-1818 (1990).	
	IL	WILSON, L.J., *et al.*, The Synthesis and Anti-HIV Activity of Pyrimidine Dioxolanyl Nucleosides," *Bioorganic & Medicinal Chemistry Letters*, 3(2):169-174 (1993).	
	IM	YOKOTA *et al.*, "Comparative Activities of Several Nucleoside Analogs Against Duck ...," *Antimicrob. Agents and Chemother.*, 34(7):1326-1330 (1990).	
HD	IN	ZHU, Z., *et al.*, "Cellular Metabolism of 3'-Azido-2',3'-Dideoxyuridine with Formation of 5'-O-Diphosphohexase ..." *Molecular Pharmacology*, 38:929-938 (1990).	

Examiner Signature	Howard Cam	Date Considered	12-6-04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

* Not in file